Wu Y, Khan H, Chillar R, Vadgama J V
Department of Medicine, Divisions of Laboratory Research and Development and Hematology/Oncology, Charles R. Drew University of Medicine and Science, UCLA School of Medicine, Los Angeles, CA 90059, USA.
Int J Oncol. 1999 Jun;14(6):1021-37. doi: 10.3892/ijo.14.6.1021.
We examined the significance of plasma HER-2/neu as a clinical or biological marker for assessing the progression of breast cancer in African American and Hispanic women with similar socioeconomic status, similar health insurance, and similar access to health care delivery. Base line studies show the following: average age of our breast cancer patients was 48 for Hispanic and 53 for African American women. Most of our patients presented invasive ductal carcinoma, and there was no ethnic difference. A larger number of Hispanic women had stage III/IV disease at the time of diagnosis. There was no significant difference in the number of African American or Hispanic patients with ER positive or negative receptors. However, a larger number of Hispanic women had PR positive tumors, and a larger number of African American women had PR negative tumors. In general, there was no difference in the levels of HER-2/neu between the two ethnic groups. Patients with tumors >5 cm had elevated plasma HER-2/neu. However, there was no ethnic difference between tumor size and HER-2/neu levels. In addition, regional node status had no impact on plasma HER-2/neu. Patients with stage III/IV tumors had elevated plasma HER-2/neu. No ethnic difference was observed at either stage I/II or III/IV. ER positive or negative status had no significant impact on plasma HER-2/neu in either ethnic group. In contrast, PR positive patients showed elevated plasma HER-2/neu. Plasma HER-2/neu (>60 U/ml) was the strongest predictor of overall survival, visceral site metastasis, and local recurrence.
我们研究了血浆HER-2/neu作为临床或生物学标志物，在社会经济地位、医疗保险和获得医疗服务相似的非裔美国和西班牙裔女性中评估乳腺癌进展情况的意义。基线研究显示如下：我们的乳腺癌患者中，西班牙裔女性的平均年龄为48岁，非裔美国女性为53岁。我们的大多数患者表现为浸润性导管癌，且不存在种族差异。更多西班牙裔女性在诊断时患有III/IV期疾病。非裔美国或西班牙裔患者中雌激素受体阳性或阴性的数量没有显著差异。然而，更多西班牙裔女性患有孕激素受体阳性肿瘤，更多非裔美国女性患有孕激素受体阴性肿瘤。总体而言，两个种族群体之间HER-2/neu水平没有差异。肿瘤>5 cm的患者血浆HER-2/neu升高。然而，肿瘤大小与HER-2/neu水平之间不存在种族差异。此外，区域淋巴结状态对血浆HER-2/neu没有影响。III/IV期肿瘤患者的血浆HER-2/neu升高。在I/II期或III/IV期均未观察到种族差异。雌激素受体阳性或阴性状态对任何一个种族群体的血浆HER-2/neu均无显著影响。相比之下，孕激素受体阳性患者的血浆HER-2/neu升高。血浆HER-2/neu（>60 U/ml）是总生存期、内脏部位转移和局部复发的最强预测指标。
